University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor

Bruce A. Cree, Ph.D., M.D.

Neurologist

Dr. Bruce Cree is a neurologist with a special interest in multiple sclerosis. In addition to providing patient care, Cree focuses on the development of novel therapies through clinical trials. Cree received his medical degree and doctorate in biochemistry from the University of California, San Francisco. He went on to complete his neurology residency at Columbia University. Cree is the recipient of a National Institute of Health post-doctoral grant for multiple sclerosis clinical research and is a Sylvia Lawry fellow of the National Multiple Sclerosis Society.

Clinics

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

More about Bruce A. Cree

Education

UCSF School of Medicine 1997

Residencies

Columbia Presbyterian Medical Center, Neurology 2001

Fellowships

UCSF Medical Center, Neurology 2003

Selected Research and Publications

  1. Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol. 2013 Feb; 70(2):248-51.
  2. von Büdingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, Cree BA, Gourraud PA, Schwartzburg A, Huerta G, Telman D, Sundar PD, Casey T, Cox DR, Hauser SL. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 2012 Dec 3; 122(12):4533-43.
  3. West TW, Hess C, Cree BA. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012 Apr; 32(2):97-113.
  4. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012 Jul; 72(1):53-64.
  5. Menge T, Cree B, Saleh A, Waterboer T, Berthele A, Kalluri SR, Hemmer B, Aktas O, Hartung HP, Methner A, Kieseier BC. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 2012 Jul 17; 79(3):285-7.
  6. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 Aug 11; 476(7359):214-9.
  7. Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, Mowry EM, Miller JW, Hauser SL, Green AJ. Vitamin D in African Americans with multiple sclerosis. Neurology. 2011 May 24; 76(21):1824-30.
  8. Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, Vincent T, Fujihara K, Itoyama Y, Bar-Or A. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011 Jul; 18(7):997-8.
  9. Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011 Apr; 68(4):464-8.
  10. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011; 6(2):e16664.
  11. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011 Feb 22; 76(8):686-92.
  12. Woolley J, Douglas VC, Cree BA. Neuromyelitis optica, psychiatric symptoms and primary polydipsia: a case report. Gen Hosp Psychiatry. 2010 Nov-Dec; 32(6):648.e5-8.
  13. Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, Bennett JL, Berthele A, Hemmer B. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol. 2010 Oct; 67(10):1201-8.
  14. Cree BA. Diagnosis and differential diagnosis of multiple sclerosis. Continuum (Minneap Minn). 2010 Oct; 16(5 Multiple Sclerosis):19-36.
  15. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol. 2010 Sep; 68(3):395-9.
  16. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2):145-50.
  17. Cree BA, Rioux JD, McCauley JL, Gourraud PA, Goyette P, McElroy J, De Jager P, Santaniello A, Vyse TJ, Gregersen PK, Mirel D, Hafler DA, Haines JL, Pericak-Vance MA, Compston A, Sawcer SJ, Oksenberg JR, Hauser SL. A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS One. 2010; 5(6):e11296.
  18. McElroy JP, Cree BA, Caillier SJ, Gregersen PK, Herbert J, Khan OA, Freudenberg J, Lee A, Bridges SL, Hauser SL, Oksenberg JR, Gourraud PA. Refining the association of MHC with multiple sclerosis in African Americans. Hum Mol Genet. 2010 Aug 1; 19(15):3080-8.
  19. Cree B, Waubant E. Does race matter for multiple sclerosis? Neurology. 2010 Feb 16; 74(7):532-3.
  20. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A. 2009 Nov 3; 106(44):18680-5.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.